Skip to main content

Advertisement

SpringerLink
Log in

Diabetes, Obesity, and the Metabolic Syndrome as Prognostic Factors in Stages I to III Colorectal Cancer Patients

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Attempts to introduce prognostic factors for survival outcomes in localized colorectal cancer patients receiving surgical treatment with or without adjuvant therapies, beyond the classic staging parameters, have been met with limited success. Obesity and diabetes mellitus are among the conditions that predispose to colorectal cancer but their value as prognostic markers once the disease is diagnosed is controversial.

Patients and Methods

This study examines the prognostic value of the components of metabolic syndrome in a retrospective series of colorectal cancer patients with stages I to III disease followed in a single center.

Results

Among the four components of the metabolic syndrome, only diabetes was independently associated with progression-free survival (PFS) while obesity, hypertension, and dyslipidemia were not. No associations of the metabolic syndrome (MS) or its components with overall survival (OS) were observed in multivariate analysis.

Conclusion

These data pinpoint to diabetes mellitus (DM) as a possible prognostic factor for PFS in localized colorectal cancer and further cast doubt for the value of obesity as measured by body mass index (BMI) on local stage colorectal cancer prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kinzler LW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87(2):159–70. https://doi.org/10.1016/S0092-8674(00)81333-1.

    Article  CAS  PubMed  Google Scholar 

  2. Voutsadakis IA. Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med. 2007;11(2):252–85. https://doi.org/10.1111/j.1582-4934.2007.00032.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ansary Moghaddam A, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomark Prev. 2007;16:2533–47.

    Article  Google Scholar 

  4. Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011;106(11):1911–22. https://doi.org/10.1038/ajg.2011.301.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Voutsadakis IA Obesity and diabetes as prognostic factors in patients with colorectal cancer. Diab Metab Syndr. 2017;11(Suppl 1):S109–S114. https://doi.org/10.1016/j.dsx.2016.12.018.

  6. Pais R, Silaghi H, Silaghi AC, et al (2009) Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 15:5141–5148.

  7. Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013;119(8):1528–36. https://doi.org/10.1002/cncr.27938.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yang Y, Mauldin PD, Ebeling M, Hulsey TC, Liu B, Thomas MB, et al. Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients. Cancer. 2013;119(8):1512–20. https://doi.org/10.1002/cncr.27923.

    Article  PubMed  Google Scholar 

  9. Amptoulach S, Gross G, Kalaitzakis E (2015) Differential impact of obesity and diabetes mellitus on survival after liver resection for colorectal cancer metastases. J Surg Res 199: 378–385.

  10. Ottaiano A, Nappi A, Tafuto S et al (2016) Diabetes and body mass index are associated with neuropathy and prognosis in colon cancer patients treated with capecitabine and oxaliplatin adjuvant chemotherapy. Oncologia 90: 36–42.

  11. Peng F, Hu D, Lin X, Chen G, Liang B, Zhang H, et al. Preoperative metabolic syndrome and prognosis after radical resection for colorectal for colorectal cancer: the Fujian prospective investigation of cancer (FIESTA) study. Int J Cancer. 2016;139(12):2705–13. https://doi.org/10.1002/ijc.30404.

    Article  CAS  PubMed  Google Scholar 

  12. You J, Liu W-Y, Zhu G-Q. Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer. Oncotarget. 2015;6(23):19880–90. https://doi.org/10.18632/oncotarget.4166.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ahmadi A, Noroozi M, Pourhoseingholi MA, Hashemi-Nazari S-S. Effect of metabolic syndrome and its components on survival in colorectal cancer: a prospective study. J Renal Inj Prev. 2015;4(1):15–9. https://doi.org/10.12861/jrip.2015.05.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhu B, Wu X, Wu B, Pei D, Zhang L, Wei L. The relationship between diabetes and colorectal cancer prognosis: a meta-analysis based on the cohort studies. PLoS One. 2017;12(4):e0176068. https://doi.org/10.1371/journal.pone.0176068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from cancer and leukemia group B 89803. J Clin Oncol. 2008;26:4109–15.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Dignam JJ, Poitre BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98(22):1647–54. https://doi.org/10.1093/jnci/djj442.

    Article  PubMed  Google Scholar 

  17. Siegel EM, Ulrich CM, Poole EM, Holmes RS, Jacobsen PB, Shibata D. The effects of obesity and obesity-related conditions on colorectal cancer prognosis. Cancer Control. 2010;17(1):52–7. https://doi.org/10.1177/107327481001700107.

    Article  PubMed  Google Scholar 

  18. Sinicrope FA, Foster NR, Sargent DJ, O'Connell MJ, Rankin C. Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res. 2010;16(6):1884–93. https://doi.org/10.1158/1078-0432.CCR-09-2636.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Anderson BJ, Wahlquist AE, Hill EG, Marshall DT, Kimchi ET, Staveley O'Carroll KF, et al. The impact of metabolic syndrome on outcome and response to neoadjuvant chemoradiation in locally advanced rectal cancer patients. Int J Surg. 2016;33:8–12. https://doi.org/10.1016/j.ijsu.2016.07.011.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Fransgaard T, Thygesen LC, Gögenur I. Metformin increases overall survival in patients with diabetes undergoing surgery for colorectal cancer. Ann Surg Oncol. 2016;23(5):1569–75. https://doi.org/10.1245/s10434-015-5028-8.

    Article  PubMed  Google Scholar 

  21. Ramjeesingh R, Orr C, Bricks CS, et al. A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival. Curr Oncol. 2016;23:e116–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Mei Z-B, Zhang Z-J, Liu C, et al. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS One. 2014;9(3):e91818. https://doi.org/10.1371/journal.pone.0091818.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Vigneri PG, Tirrò E, Pennisi MS, et al. The insulin/IGF system in colorectal cancer development and resistance to therapy. Front Oncol. 2015;5:230.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Yao C, Su L, Shan J, Zhu C, Liu L, Liu C, et al. IGF/ STAT3/ NANOG/ slug signaling axis simultaneously controls epithelial-mesenchymal transition and stemness maintenance in colorectal cancer. Stem Cells. 2016;34(4):820–31. https://doi.org/10.1002/stem.2320.

    Article  CAS  PubMed  Google Scholar 

  25. Li H, Singh Batth I, Qu X, et al. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Mol Cancer. 2017;16(6):6. https://doi.org/10.1186/s12943-016-0576-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Tudzarova S, Osman MA. The double trouble of metabolic diseases: the diabetes-cancer link. Mol Biol Cell. 2015;26(18):3129–39. https://doi.org/10.1091/mbc.E14-11-1550.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The study was supported by a grant by the Sault Ste. Marie Academic Medical Association, Ontario, Canada (to I.A. Voutsadakis).

Author information

Authors and Affiliations

  1. Clinical Trials Unit, Sault Area Hospital, Sault Ste Marie, Ontario, Canada

    Brianna Croft, Melissa Reed, Caitlyn Patrick & Natalie Kovacevich

  2. Algoma District Cancer Program, Sault Area Hospital, Sault Ste Marie, Ontario, P6B 0A8, Canada

    Ioannis A. Voutsadakis

  3. Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, Ontario, Canada

    Ioannis A. Voutsadakis

Authors
  1. Brianna Croft
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melissa Reed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caitlyn Patrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Natalie Kovacevich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ioannis A. Voutsadakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ioannis A. Voutsadakis.

Ethics declarations

The study protocol was approved by the Institutional Ethics Review Board of Sault Area Hospital.

Conflict of Interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Croft, B., Reed, M., Patrick, C. et al. Diabetes, Obesity, and the Metabolic Syndrome as Prognostic Factors in Stages I to III Colorectal Cancer Patients. J Gastrointest Canc 50, 221–229 (2019). https://doi.org/10.1007/s12029-018-0056-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-018-0056-9

Keywords

Search

Navigation